Crohn Disease
|
0.430 |
GeneticVariation
|
disease |
BEFREE |
Colon-only CD (n = 228) was compared with healthy controls: three of six UC SNPs (in MST1, HLA-DRA, and IL-23R) and 11 of 34 CD SNPs: in IRGM, NOD2 (rs2066845), CCNY, MST1, IL23R, PTPN22, C11orf30, ZNF365, PTPN2, PSMG1, and rs1456893 were significantly associated.
|
21830272 |
2011 |
Crohn Disease
|
0.430 |
GeneticVariation
|
disease |
BEFREE |
We identified multiple previously unreported or unconfirmed disease associations, including known CD loci (ICOSLG and TNFSF15) and T1D loci (TNFAIP3) that confer UC risk, known UC loci (HERC2 and IL26) that confer T1D risk and known UC loci (IL10 and CCNY) that confer CD risk.
|
20176734 |
2010 |
Crohn Disease
|
0.430 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.
|
18587394 |
2008 |
Crohn Disease
|
0.430 |
GeneticVariation
|
disease |
LHGDN |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
Crohn Disease
|
0.430 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
Ulcerative Colitis
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
|
21297633 |
2011 |
Ulcerative Colitis
|
0.420 |
GeneticVariation
|
disease |
GWASDB |
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
|
21297633 |
2011 |
Ulcerative Colitis
|
0.420 |
GeneticVariation
|
disease |
BEFREE |
We identified multiple previously unreported or unconfirmed disease associations, including known CD loci (ICOSLG and TNFSF15) and T1D loci (TNFAIP3) that confer UC risk, known UC loci (HERC2 and IL26) that confer T1D risk and known UC loci (IL10 and CCNY) that confer CD risk.
|
20176734 |
2010 |
Ulcerative Colitis
|
0.420 |
GeneticVariation
|
disease |
BEFREE |
Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.
|
18438405 |
2008 |
Ulcerative Colitis
|
0.420 |
Biomarker
|
disease |
CTD_human |
Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.
|
18438405 |
2008 |
Ulcerative Colitis
|
0.420 |
GeneticVariation
|
disease |
LHGDN |
Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.
|
18438405 |
2008 |
Crohn's disease of large bowel
|
0.300 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
Crohn's disease of the ileum
|
0.300 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
Regional enteritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
IIeocolitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
With further analysis of the CCNY levels, there were no differences in age, sex, smoking status, tumor location, histologic subtype, or tumor size, but differences were observed in lymphatic (<i>P</i><0.001) and distant (<i>P</i><0.001) metastases in NSCLC patients.
|
30774378 |
2019 |
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
CCNY, a novel cyclin family member, plays an increasingly important role in the progression of tumor invasion and metastasis, including lung cancer.
|
30774378 |
2019 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.
|
29557391 |
2018 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We also identified recurrent focal amplification of gene CCNY derived from BFB in two metastatic tumors, but not in primary tumor.
|
28381877 |
2017 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Moreover, in a Cox regression analysis, anti-CCNY autoantibody was an independent factor that predicted poor prognosis for postoperative patients with early-stage NSCLC (P = 0.026) as well as for those with distant metastasis (P = 0.012).
|
24167380 |
2013 |
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Serum anti-CCNY autoantibody is an independent prognosis indicator for postoperative patients with early-stage nonsmall-cell lung carcinoma.
|
24167380 |
2013 |
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Hence, the aim of this study was to explore the potential role of CCNY in lung cancer.
|
21273179 |
2011 |
Carcinoma of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The expression status of CCNY in lung cancer and its clinical significance remain unknown.
|
20596919 |
2010 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We identified several candidates implicating the CDK16/CCNY complex in cytoskeletal dynamics, and we focused on the microtubule-associated protein regulator of cytokinesis (PRC1), an essential protein for cell division that organizes antiparallel microtubules and whose deregulation may drive genomic instability in cancer.
|
30992425 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the training set, serum CCNY was markedly increased in the NSCLC patients (<i>P</i><0.05) with an integrated area under the curve of 0.751.
|
30774378 |
2019 |